Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Dr. Reddy’s Methylphenidate Hydrochloride Extended-Release Tablets, USP are available in strengths of 18 mg, 27 mg, 36 mg, and 54 mg tablets in bottle count sizes of 100.
Product Name : Methylphenidate Hydrochloride-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
September 03, 2020
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Collegium Pharmaceutical
Deal Size : $550.0 million
Deal Type : Acquisition
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
Details : Collegium will acquire Ironshore, which will help to expand into neurology, which includes JORNAY PM (methylphenidate HCl). It is indicated for the treatment of ADHD in patients 6 years and older.
Product Name : Jornay PM
Product Type : Small molecule
Upfront Cash : $525.0 million
July 29, 2024
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Collegium Pharmaceutical
Deal Size : $550.0 million
Deal Type : Acquisition
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Alora Pharmaceuticals, LLC Announces the Availability of Once-Daily Relexxii® for the Treatment o...
Details : Relexxii (methylphenidate HCl) is a dopamine/norepinephrine reuptake inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of attention deficit hyperactivity disor...
Product Name : Relexxii
Product Type : Small molecule
Upfront Cash : Not Applicable
December 19, 2023
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Quillivant ER (methylphenidate) Oral Suspension and Chewable Tablet R is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.
Product Name : Quillivant ER
Product Type : Small molecule
Upfront Cash : Not Applicable
September 25, 2023
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Teva Pharmaceutical Industries
Deal Size : Not Applicable
Deal Type : Not Applicable
Tris Pharma Announces US District Court Upholds Validity of QuilliChew ER® Patents; Rules Teva In...
Details : QuilliChew ER (methylphenidate hydrochloride) is a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years ...
Product Name : QuilliChew
Product Type : Small molecule
Upfront Cash : Not Applicable
August 18, 2022
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Teva Pharmaceutical Industries
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Osmotica Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RELEXXII® (methylphenidate hydrochloride extended-release tablets) is an oral medication indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults up to the age of 65 and p...
Product Name : Relexxii
Product Type : Small molecule
Upfront Cash : Not Applicable
July 11, 2022
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Osmotica Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Societal CDMO
Deal Size : Undisclosed
Deal Type : Agreement
Details : Ritalin LA is indicated for the treatment of attention deficit hyperactivity disorder. The product is an extended-release formulation of methylphenidate hydrochloride with a bi-modal release profile using...
Product Name : Ritalin LA
Product Type : Small molecule
Upfront Cash : Undisclosed
May 05, 2022
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Societal CDMO
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : InfectoPharm Drugs and Consilium
Deal Size : Undisclosed
Deal Type : Agreement
Details : Ritalin LA is indicated for the treatment of attention deficit hyperactivity disorder. The product is an extended-release formulation of methylphenidate hydrochloride with a bi-modal release profile using...
Product Name : Ritalin LA
Product Type : Small molecule
Upfront Cash : Undisclosed
May 05, 2022
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : InfectoPharm Drugs and Consilium
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Supplemental New Drug Application for Adhansia XR® (methylphenidate HCl) Extended-Re...
Details : The sNDA approval was based on data from a randomized, double-blind, parallel-group, placebo-controlled, Phase 3 Adult Laboratory Classroom (ALC) study evaluating the safety and efficacy of Adhansia XR in...
Product Name : Adhansia XR
Product Type : Small molecule
Upfront Cash : Not Applicable
July 01, 2021
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Medison Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the licensing agreement, Medison has been granted exclusive rights to commercialize Tris’ FDA-approved Quillivant XR in Israel.
Product Name : Quillivant XR
Product Type : Small molecule
Upfront Cash : Undisclosed
November 17, 2020
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Medison Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?